Previous 10 | Next 10 |
Type C Meeting confirmed that FDA does not believe additional clinical safety, efficacy, or pharmacology studies will be required to support NDA resubmission Company successfully completed the first of two planned human factors studies Company accelerates timeline ...
BURLINGTON, Mass., Aug. 06, 2019 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, t...
Gainers: Nautilus (NYSE: NLS ) +21% . Francesca's Holdings (NASDAQ: FRAN ) +20% . Anixa Biosciences (NASDAQ: ANIX ) +19% . AVROBIO (NASDAQ: AVRO ) +19% . Rekor Systems (REKR) +18% . Seattle Genetics (NASDAQ: SGEN ) +18% . Hill International (NYSE: HIL ) +18% . scPharmaceutical...
Thinly traded nano cap scPharmaceuticals (NASDAQ: SCPH ) is up 4% premarket on light volume in response to a more bullish timeline for the filing of a U.S. marketing application for lead candidate FUROSCIX for the treatment of congestion in heart failure patients. More news o...
Type C Meeting confirmed that FDA does not believe additional clinical safety, efficacy, or pharmacology studies will be required to support NDA resubmission and review FDA confirmed that the resubmission would be under the current NDA Company accelerates timeline and now expects ...
BURLINGTON, Mass., May 30, 2019 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, to...
scPharmaceuticals (NASDAQ: SCPH ): Q1 GAAP EPS of -$0.47 beats by $0.05. More news on: scPharmaceuticals Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
Type C Meeting to solidify re-filing plans for FUROSCIX® scheduled with the U.S. Food and Drug Administration (FDA) for June 2019 Resubmission of FURSOCIX New Drug Application (NDA) with the FDA in 2020 Balance sheet remains strong with over $83 million in cash BURLINGTON,...
"Purgatory is hell with hope. ” ― Philip José Farmer The biotech sector is off to a very tough start this Wednesday in what feels like a lot of algorithmic trading as the market is flat, and there is not a lot of news around the sector to account for the drop. Just befo...
Gainers : Rexahn Pharmaceuticals (NYSEMKT: RNN ) +28% . UP Fintech Holding (NASDAQ: TIGR ) +21% . Iconix Brand Group (NASDAQ: ICON ) +22% . ReWalk Robotics (NASDAQ: RWLK ) +16% . Future FinTech Group (NASDAQ: FTFT ) +13% . 360 Finance (NASDAQ: QFIN ) +13% . FTS International (NY...
News, Short Squeeze, Breakout and More Instantly...
scPharmaceuticals Inc. Company Name:
SCPH Stock Symbol:
NASDAQ Market:
scPharmaceuticals Inc. Website:
BURLINGTON, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today an...
A look at the top 10 most actives in the United States SiNtx Technologies Inc. (SINT) rose 208.7% to $0.1698 on volume of 325,435,783 shares Faraday Future Intelligent Electric Inc. (FFIE) rose 76.7% to $0.5039 on volume of 314,353,673 shares Greenwave Technology Solutions Inc. (GWAV) ros...
Generated 1Q 2024 net FUROSCIX ® revenue of $6.1 million, despite an estimated 10% impact to doses filled resulting from the Change Healthcare cyberattack Ended 1Q 2024 with cash and cash equivalents o f $58.4 million Company to host investor conference call and web...